The IDIBAPS Board of Governors has approved the creation of a new research group. The decision follows the scientific evaluation of the researchers –1

Clínic Barcelona

Institutional September 22 2022

The Hospital Clínic starts an immunotherapy trial based on tumour-infiltrating lymphocytes (TILs) in triple-negative breast cancer

Trial TILs001, which is open to patients with metastatic triple-negative breast cancer, is the first study to assess the safety and efficacy of TILs1

News about Immunotherapy

IDIBAPS establishes a new research group devoted to cellular immunotherapies aimed at combatting cancer

The Hospital Clínic starts an immunotherapy trial based on tumour-infiltrating lymphocytes (TILs) in triple-negative breast cancer

Subscribe to the Newsletter of Clínic